Molecular targets and mechanism of action of dexmedetomidine in treatment of ischemia/reperfusion injury (Review)

Molecular Medicine Reports

Volumn 9, Issue 5, 2014, Pages 1542-1550

  Cai, Y E ^a   Xu, Hui ^a   Yan, Jia ^a   Zhang, Lei ^a   Lu, Y I ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Dexmedetomidine; Ischemia reperfusion; Treatment

Indexed keywords

ADENOSINE TRIPHOSPHATE; DEXMEDETOMIDINE; HEAT SHOCK PROTEIN 70; ION CHANNEL; MALONALDEHYDE; MESSENGER RNA; PROTEIN C FOS; SUPEROXIDE DISMUTASE;

ANTIOXIDANT ACTIVITY; BRAIN INJURY; DNA POLYMORPHISM; DRUG TARGETING; ERYTHROCYTE DEFORMABILITY; EXCITOTOXICITY; GENETIC REGULATION; HEART MUSCLE INJURY; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; INFLAMMATION; INNATE IMMUNITY; INSULIN RELEASE; KIDNEY TUBULE ABSORPTION; LOCUS CERULEUS; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; ORGAN TRANSPLANTATION; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; SPINE INJURY; VASOCONSTRICTION;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ANIMALS; CALCIUM; DEXMEDETOMIDINE; HUMANS; INFLAMMATION; ION CHANNELS; MOLECULAR TARGETED THERAPY; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; REGIONAL BLOOD FLOW; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 84899497014     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2034     Document Type: Review

References (94)

1. McCutcheon CA, Orme RM, Scott DA, Davies MJ and McGlade DP: A comparison of dexmedetomidine versus conventional therapy for sedation and hemodynamic control during carotid endarterectomy performed under regional anesthesia. Anesth Analg 102: 668-675, 2006.
2. Ramsay MA and Luterman DL: Dexmedetomidine as a total intravenous anesthetic agent. Anesthesiology 101: 787-790, 2004. (Pubitemid 39121659)
3. Billings FT 4th, Chen SW, Kim M, et al: alpha2-Adrenergic agonists protect against radiocontrast-induced nephropathy in mice. Am J Physiol Renal Physiol 295: F741-F748, 2008.
4. Multz AS: Prolonged dexmedetomidine infusion as an adjunct in treating sedation-induced withdrawal. Anesth Analg 96:1054-1055, 2003.
5. Paris A, Mantz J, Tonner PH, Hein L, Brede M and Gressens P: The effects of dexmedetomidine on perinatal excitotoxic brain injury are mediated by the alpha2A-adrenoceptor subtype. Anesth Analg 102: 456-461, 2006. (Pubitemid 43152595)
6. Land W, Schneeberger H, Schleibner S, et al: The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 57: 211-217, 1994. (Pubitemid 24048587)
7. Land WG: The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation 79: 505-514, 2005.
8. O'Neill S, Ross JA, Wigmore SJ and Harrison EM: The role of heat shock protein 90 in modulating ischemia-reperfusion injury in the kidney. Expert Opin Investig Drugs 21: 1535-1548, 2012.
9. Malis CD and Bonventre JV: Mechanism of calcium potentiation of oxygen free radical injury to renal mitochondria. A model for post-ischemic and toxic mitochondrial damage. J Biol Chem 261:14201-14208, 1986. (Pubitemid 17196327)
10. Wang QM, Stalker TJ, Gong Y, Rikitake Y, Scalia R and Liao JK: Inhibition of Rho-kinase attenuates endothelial-leukocyte interaction during ischemia-reperfusion injury. Vasc Med 17:379-385, 2012.
11. Wittner M, Sivenius J and Koistinaho J: Alpha2-adrenoreceptor agonist, dexmedetomidine, alters acute gene expression after global ischemia in gerbils. Neurosci Lett 232: 75-78, 1997. (Pubitemid 27394489)
12. Muszkat M, Kurnik D, Solus J, et al: Variation in the alpha2B-adrenergic receptor gene (ADRA2B) and its relationship to vascular response in vivo. Pharmacogenet Genomics 15:407-414, 2005. (Pubitemid 40835082)
13. Yaǧar S, Yavaş S and Karahalil B: The role of the ADRA2A C1291G genetic polymorphism in response to dexmedetomidine on patients undergoing coronary artery surgery. Mol Biol Rep 38: 3383-3389, 2011.
14. 2-Adrenoceptor agonist dexmedetomidine protects septic acute kidney injury through increasing BMP-7 and inhibiting HDAC2 and HDAC5. Am J Physiol Renal Physiol 303: F1443-F1453, 2012.
15. Gu J, Sun P, Zhao H, et al: Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice. Crit Care 15: R153, 2011.
16. Dahmani S, Rouelle D, Gressens P and Mantz J: Effects of dexmedetomidine on hippocampal focal adhesion kinase tyrosine phosphorylation in physiologic and ischemic conditions. Anesthesiology 103: 969-977, 2005. (Pubitemid 41552052)
17. Chang Y, Huang X, Liu Z, et al: Dexmedetomidine inhibits the secretion of high mobility group box 1 from lipopolysaccharide-activated macrophages in vitro. J Surg Res 181: 308-314, 2013.
18. Chiu TH, Chen MJ, Yang YR, Yang JJ and Tang FI: Action of dexmedetomidine on rat locus coeruleus neurones: intracellular recording in vitro. Eur J Pharmacol 285: 261-268, 1995.
19. Shirasaka T, Kannan H and Takasaki M: Activation of a G protein-coupled inwardly rectifying K+ current and suppression of Ih contribute to dexmedetomidine-induced inhibition of rat hypothalamic paraventricular nucleus neurons. Anesthesiology 107: 605-615, 2007. (Pubitemid 47480567)
20. Chen BS, Peng H and Wu SN: Dexmedetomidine, an alpha2-adrenergic agonist, inhibits neuronal delayed-rectifier potassium current and sodium current. Br J Anaesth 103: 244-254, 2009.
21. +-ketamine in ischemia and reperfusion injury in the rat kidney. Acta Cir Bras 26: 202-206, 2011.
22. Tanabe K, Takai S, Matsushima-Nishiwaki R, Kato K, Dohi S and Kozawa O: Alpha2 adrenoreceptor agonist regulates protein kinase C-induced heat shock protein 27 phosphorylation in C6 glioma cells. J Neurochem 106: 519-528, 2008.
23. Girault JA, Costa A, Derkinderen P, Studler JM and Toutant M: FAK and PYK2/CAKbeta in the nervous system: a link between neuronal activity, plasticity and survival? Trends Neurosci 22: 257-263, 1999. (Pubitemid 29259992)
24. Parcellier A, Tintignac LA, Zhuravleva E and Hemmings BA: PKB and the mitochondria: AKTing on apoptosis. Cell Signal 20: 21-30, 2008. (Pubitemid 350138366)
25. Dahmani S, Paris A, Jannier V, et al: Dexmedetomidine increases hippocampal phosphorylated extracellular signal-regulated protein kinase 1 and 2 content by an alpha 2-adrenoceptor-independent mechanism: evidence for the involvement of imidazoline I1 receptors. Anesthesiology 108: 457-466, 2008. (Pubitemid 351304239)
26. Dahmani S, Rouelle D, Gressens P and Mantz J: Characterization of the postconditioning effect of dexmedetomidine in mouse organotypic hippocampal slice cultures exposed to oxygen and glucose deprivation. Anesthesiology 112: 373-383, 2010.
27. Zhu YM, Wang CC, Chen L, et al: Both PI3K/Akt and ERK1/2 pathways participate in the protection by dexmedetomidine against transient focal cerebral ischemia/reperfusion injury in rats. Brain Res 1494: 1-8, 2013.
28. Takamatsu I, Iwase A, Ozaki M, Kazama T, Wada K and Sekiguchi M: Dexmedetomidine reduces long-term potentiation in mouse hippocampus. Anesthesiology 108: 94-102, 2008.
29. Du T, Li B, Liu S, et al: ERK phosphorylation in intact, adult brain by alpha(2)-adrenergic transactivation of EGF receptors. Neurochem Int 55: 593-600, 2009.
30. Schaak S, Cussac D, Cayla C, et al: Alpha(2) adrenoceptors regulate proliferation of human intestinal epithelial cells. Gut 47: 242-250, 2000. (Pubitemid 30489768)
31. Cussac D, Schaak S, Gales C, Flordellis C, Denis C and Paris H: alpha(2B)-Adrenergic receptors activate MAPK and modulate proliferation of primary cultured proximal tubule cells. Am J Physiol Renal Physiol 282: F943-F952, 2002. (Pubitemid 34654500)
32. Hanci V, Yurdakan G, Yurtlu S, Turan IÖ and Sipahi EY: Protective effect of dexmedetomidine in a rat model of α-naphthylthiourea-induced acute lung injury. J Surg Res 178: 424-430, 2012.
33. Niittykoski M, Haapalinna A and Sirviö J: Diminution of N-methyl-D-aspartate-induced perturbation of neurotransmission by dexmedetomidine in the CA1 field of rat hippocampus in vitro. Neurosci Lett 281: 95-98, 2000. (Pubitemid 30125874)
34. Kim HJ, Sohn JT, Jeong YS, et al: Direct effect of dexmedetomidine on rat isolated aorta involves endothelial nitric oxide synthesis and activation of the lipoxygenase pathway. Clin Exp Pharmacol Physiol 36: 406-412, 2009.
35. Kiliç K, Hanci V, Selek S, et al: The effects of dexmedetomidine on mesenteric arterial occlusion-associated gut ischemia and reperfusion-induced gut and kidney injury in rabbits. J Surg Res 178: 223-232, 2012.
36. Yan M, Dai H, Ding T, et al: Effects of dexmedetomidine on the release of glial cell line-derived neurotrophic factor from rat astrocyte cells. Neurochem Int 58: 549-557, 2011.
37. Hirota K, Nomura H, Kudo M, Mori N, Kudo T and Kushikata T: Supraclinical concentrations of dexmedetomidine evoke norepinephrine release from rat cerebrocortical slices possible involvement of the orexin-1 receptor. Neurosci Lett 372: 142-145, 2004. (Pubitemid 39505245)
38. Globus MY, Busto R, Dietrich WD, Martinez E, Valdés I and Ginsberg MD: Direct evidence for acute and massive norepinephrine release in the hippocampus during transient ischemia. J Cereb Blood Flow Metab 9: 892-896, 1989. (Pubitemid 20006909)
39. Matsumoto M, Zornow MH, Rabin BC and Maze M: The alpha 2 adrenergic agonist, dexmedetomidine, selectively attenuates ischemia-induced increases in striatal norepinephrine concentrations. Brain Res 627: 325-329, 1993. (Pubitemid 23313271)
40. Maier C, Steinberg GK, Sun GH, Zhi GT and Maze M: Neuroprotection by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology 79: 306-312, 1993. (Pubitemid 23224843)
41. Eser O, Fidan H, Sahin O, et al: The influence of dexmedetomidine on ischemic rat hippocampus. Brain Res 1218: 250-256, 2008.
42. Chiu KM, Lin TY, Lu CW and Wang SJ: Inhibitory effect of glutamate release from rat cerebrocortical nerve terminals by α2 adrenoceptor agonist dexmedetomidine. Eur J Pharmacol 670: 137-147, 2011.
43. Bickler PE and Hansen BM: Alpha 2-adrenergic agonists reduce glutamate release and glutamate receptor-mediated calcium changes in hippocampal slices during hypoxia. Neuropharmacology 35: 679-687, 1996. (Pubitemid 26308544)
44. Talke P and Bickler PE: Effects of dexmedetomidine on hypoxia-evoked glutamate release and glutamate receptor activity in hippocampal slices. Anesthesiology 85: 551-557, 1996. (Pubitemid 26332608)
45. Engelhard K, Werner C, Kaspar S, et al: Effect of the alpha2-agonist dexmedetomidine on cerebral neurotransmitter concentrations during cerebral ischemia in rats. Anesthesiology 96: 450-457, 2002. (Pubitemid 34121758)
46. Valtonen P, Haapalinna A, Riekkinen P Sr and Halonen T: Effect of alpha 2-adrenergic drugs dexmedetomidine and atipamezole on extracellular amino acid levels in vivo. Eur J Pharmacol 285: 239-246, 1995.
47. Kose EA, Bakar B, Kasimcan O, et al: Effects of intracisternal dexmedetomidine on cerebral neuronal cells in rat: a preliminary study. Turk Neurosurg 23: 38-44, 2013.
48. Kodera SY, Yoshida M, Dezaki K, et al: Inhibition of insulin secretion from rat pancreatic islets by dexmedetomidine and medetomidine, two sedatives frequently used in clinical settings. Endocr J 60: 337-346, 2013.
49. Kurt A, Ingec M, Isaoglu U, et al: An investigation about the inhibition of acute ischemia/reperfusion damage by dexmedetomidine in rat ovarian tissue. Gynecol Endocrinol 29: 222-225, 2013.
50. Hayashida K and Eisenach JC: Spinal α2-adrenoceptor-mediated analgesia in neuropathic pain reflects brain-derived nerve growth factor and changes in spinal cholinergic neuronal function. Anesthesiology 113: 406-412, 2010.
51. Peng L, Li B, Du T, et al: Astrocytic transactivation by alpha2A-adrenergic and 5-HT2B serotonergic signaling. Neurochem Int 57: 421-431, 2010.
52. Holers VM and Kulik L: Complement receptor 2, natural antibodies and innate immunity: Inter-relationships in B cell selection and activation. Mol Immunol 44: 64-72, 2007. (Pubitemid 44647113)
53. Fritz JH, Ferrero RL, Philpott DJ and Girardin SE: Nod-like proteins in immunity, inflammation and disease. Nat Immunol 7: 1250-1257, 2006. (Pubitemid 46111242)
54. Sezer A, Memiş D, Usta U and Süt N: The effect of dexmedetomidine on liver histopathology in a rat sepsis model: an experimental pilot study. Ulus Travma Acil Cerrahi Derg 16: 108-112, 2010.
55. Venn RM, Bryant A, Hall GM and Grounds RM: Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in the intensive care unit. Br J Anaesth 86: 650-656, 2001. (Pubitemid 32409406)
56. Tasdogan M, Memis D, Sut N and Yuksel M: Results of a pilot study on the effects of propofol and dexmedetomidine on inflammatory responses and intraabdominal pressure in severe sepsis. J Clin Anesth 21: 394-400, 2009.
57. Lin Y, Zhu X, Yao WZ, Yang YL, A LT and Chen L: Yohimbine protects against endotoxin-induced acute lung injury by blockade of alpha 2A adrenergic receptor in rats. Chin Med J (Engl) 124: 1069-1074, 2011.
58. Kishikawa H, Kobayashi K, Takemori K, Okabe T, Ito K and Sakamoto A: The effects of dexmedetomidine on human neutrophil apoptosis. Biomed Res 29: 189-194, 2008.
59. Uysal HY, Cuzdan SS, Kayiran O, et al: Preventive effect of dexmedetomidine in ischemia-reperfusion injury. J Craniofac Surg 23: 1287-1291, 2012.
60. Lai YC, Tsai PS and Huang CJ: Effects of dexmedetomidine on regulating endotoxin-induced up-regulation of inflammatory molecules in murine macrophages. J Surg Res 154: 212-219, 2009.
61. Zhang H, Zhou F, Li C, et al: Molecular mechanisms underlying the analgesic property of intrathecal dexmedetomidine and its neurotoxicity evaluation: an in vivo and in vitro experimental study. PLoS One 8: e55556, 2013.
62. Peng M, Wang YL, Wang CY and Chen C: Dexmedetomidine attenuates lipopolysaccharide-induced proinflammatory response in primary microglia. J Surg Res 179: e219-e225, 2013.
63. Memiş D, Hekimoǧlu S, Vatan I, Yandim T, Yüksel M and Süt N: Effects of midazolam and dexmedetomidine on inflammatory responses and gastric intramucosal pH to sepsis, in critically ill patients. Br J Anaesth 98: 550-552, 2007.
64. Polat B, Albayrak Y, Suleyman B, et al: Antiulcerative effect of dexmedetomidine on indomethacin-induced gastric ulcer in rats. Pharmacol Rep 63: 518-526, 2011.
65. Walker SM, Howard RF, Keay KA and Fitzgerald M: Developmental age influences the effect of epidural dexmedetomidine on inflammatory hyperalgesia in rat pups. Anesthesiology 102: 1226-1234, 2005. (Pubitemid 40745842)
66. Happe HK, Bylund DB and Murrin LC: Alpha(2)-adrenoceptor-stimulated GTP gamma S binding in rat brain: an autoradiographic study. Eur J Pharmacol 399: 17-27, 2000. (Pubitemid 30392380)
67. Jansson CC, Pohjanoksa K, Lang J, Wurster S, Savola JM and Scheinin M: Alpha2-adrenoceptor agonists stimulate high-affinity GTPase activity in a receptor subtype-selective manner. Eur J Pharmacol 374: 137-146, 1999. (Pubitemid 29296734)
68. Lawrence CJ, Prinzen FW and de Lange S: The effect of dexmedetomidine on nutrient organ blood flow. Anesth Analg 83: 1160-1165, 1996. (Pubitemid 26418797)
69. Geze S, Cekic B, Imamoǧlu M, et al: Use of dexmedetomidine to prevent pulmonary injury after pneumoperitoneum in ventilated rats. Surg Laparosc Endosc Percutan Tech 22: 447-453, 2012.
70. Laudenbach V, Mantz J, Lagercrantz H, Desmonts JM, Evrard P and Gressens P: Effects of alpha(2)-adrenoceptor agonists on perinatal excitotoxic brain injury: comparison of clonidine and dexmedetomidine. Anesthesiology 96: 134-141, 2002. (Pubitemid 34032493)
71. Davies MF, Tsui J, Flannery JA, Li X, DeLorey TM and Hoffman BB: Activation of alpha2 adrenergic receptors suppresses fear conditioning: expression of c-Fos and phosphorylated CREB in mouse amygdala. Neuropsychopharmacology 29: 229-239, 2004. (Pubitemid 38175142)
72. Mimuro S, Katoh T, Suzuki A, et al: Deterioration of myocardial injury due to dexmedetomidine administration after myocardial ischaemia. Resuscitation 81: 1714-1717, 2010.
73. Willigers HM, Prinzen FW, Roekaerts PM, de Lange S and Durieux ME: Dexmedetomidine decreases perioperative myocardial lactate release in dogs. Anesth Analg 96: 657-664, 2003. (Pubitemid 36245547)
74. Okada H, Kurita T, Mochizuki T, Morita K and Sato S: The cardioprotective effect of dexmedetomidine on global ischaemia in isolated rat hearts. Resuscitation 74: 538-545, 2007. (Pubitemid 47176759)
75. Roekaerts PM, Prinzen FW and De Lange S: Beneficial effects of dexmedetomidine on ischaemic myocardium of anaesthetized dogs. Br J Anaesth 77: 427-429, 1996. (Pubitemid 26300878)
76. Kocoglu H, Ozturk H, Ozturk H, Yilmaz F and Gulcu N: Effect of dexmedetomidine on ischemia-reperfusion injury in rat kidney: a histopathologic study. Ren Fail 31: 70-74, 2009.
77. Marangoni MA, Hausch A, Vianna PT, Braz JR, Viero RM and Castiglia YM: Renal function and histology after acute hemorrhage in rats under dexmedetomidine action. Acta Cir Bras 22: 291-298, 2007.
78. Villela NR, do Nascimento Júnior P, de Carvalho LR and Teixeira A: Effects of dexmedetomidine on renal system and on vasopressin plasma levels. Experimental study in dogs. Rev Bras Anestesiol 55: 429-440, 2005. (Pubitemid 41032039)
79. Frumento RJ, Logginidou HG, Wahlander S, Wagener G, Playford HR and Sladen RN: Dexmedetomidine infusion is associated with enhanced renal function after thoracic surgery. J Clin Anesth 18: 422-426, 2006. (Pubitemid 44354099)
80. Bayram A, Esmaoglu A, Akin A, et al: The effects of intraoperative infusion of dexmedetomidine on early renal function after percutaneous nephrolithotomy. Acta Anaesthesiol Scand 55: 539-544, 2011.
81. Yang CL, Chen CH, Tsai PS, Wang TY and Huang CJ: Protective effects of dexmedetomidine-ketamine combination against ventilator-induced lung injury in endotoxemia rats. J Surg Res 167: e273-e281, 2011.
82. Hanci V, Erol B, Bektaş S, et al: Effect of dexmedetomidine on testicular torsion/detorsion damage in rats. Urol Int 84: 105-111, 2010.
83. Gu J, Chen J, Xia P, Tao G, Zhao H and Ma D: Dexmedetomidine attenuates remote lung injury induced by renal ischemia-reperfusion in mice. Acta Anaesthesiol Scand 55: 1272-1278, 2011.
84. Sanders RD, Xu J, Shu Y, et al: Dexmedetomidine attenuates isoflurane-induced neurocognitive impairment in neonatal rats. Anesthesiology 110: 1077-1085, 2009.
85. Bekker A, Haile M, Kline R, et al: The effect of intraoperative infusion of dexmedetomidine on the quality of recovery after major spinal surgery. J Neurosurg Anesthesiol 25: 16-24, 2013.
86. Kuhmonen J, Pokorný J, Miettinen R, et al: Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. Anesthesiology 87: 371-377, 1997. (Pubitemid 27435380)
87. Goyagi T, Nishikawa T, Tobe Y and Masaki Y: The combined neuroprotective effects of lidocaine and dexmedetomidine after transient forebrain ischemia in rats. Acta Anaesthesiol Scand 53: 1176-1183, 2009.
88. Sato K, Kimura T, Nishikawa T, Tobe Y and Masaki Y: Neuroprotective effects of a combination of dexmedetomidine and hypothermia after incomplete cerebral ischemia in rats. Acta Anaesthesiol Scand 54: 377-382, 2010.
89. Ma D, Hossain M, Rajakumaraswamy N, et al: Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol 502: 87-97, 2004. (Pubitemid 39311368)
90. Benggon M, Chen H, Applegate R, Martin R and Zhang JH: Effect of dexmedetomidine on brain edema and neurological outcomes in surgical brain injury in rats. Anesth Analg 115: 154-159, 2012.
91. Gul S, Hanci V, Bahadir B, et al: The effectiveness of dexmedetomidine in experimental spinal cord injury compared to methylprednisolone in rats. J Clin Neurosci 17: 490-494, 2010.
92. Can M, Gul S, Bektas S, Hanci V and Acikgoz S: Effects of dexmedetomidine or methylprednisolone on inflammatory responses in spinal cord injury. Acta Anaesthesiol Scand 53: 1068-1072, 2009.
93. Aslan A, Cemek M, Eser O, et al: Does dexmedetomidine reduce secondary damage after spinal cord injury? An experimental study. Eur Spine J 18: 336-344, 2009.
94. Bell MT, Puskas F, Smith PD, et al: Attenuation of spinal cord ischemia-reperfusion injury by specific α-2a receptor activation with dexmedetomidine. J Vasc Surg 56: 1398-1402, 2012.